

Atezolizumab IMvigor210 – Cohort 1

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Atezolizumab IMvigor210 – Cohort 1

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: Patients with locally advanced or metastatic UC who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression $\geq 5\%$

Experimental Arm: Atezolizumab

Control Arm: Single arm (Phase II)

